Infliximab

Generic Name
Infliximab
Brand Names
Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
Drug Type
Biotech
Chemical Formula
-
CAS Number
170277-31-3
Unique Ingredient Identifier
B72HH48FLU
Background

Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...

Indication

用于治疗：

⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；

⑵克罗恩病及瘘管性克罗恩病；

⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。

⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版

】。

⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。

Associated Conditions
Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
Associated Therapies
-
Clinical Trials
Related News

Infliximab to Treat Non-Infectious Scleritis

Phase 1
Completed
Conditions
Scleritis
First Posted Date
2004-01-01
Last Posted Date
2017-07-02
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
5
Registration Number
NCT00075075
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Study of Infliximab in Patients With Sarcoidosis

Phase 3
Completed
Conditions
Sarcoidosis
First Posted Date
2003-11-24
Last Posted Date
2011-05-17
Lead Sponsor
Centocor, Inc.
Target Recruit Count
139
Registration Number
NCT00073437

A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD

First Posted Date
2003-03-10
Last Posted Date
2011-05-17
Lead Sponsor
Centocor, Inc.
Target Recruit Count
234
Registration Number
NCT00056264

A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis

Phase 3
Completed
Conditions
Arthritis, Psoriatic
First Posted Date
2003-01-15
Last Posted Date
2011-05-17
Lead Sponsor
Centocor, Inc.
Target Recruit Count
70
Registration Number
NCT00051623

A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis

Phase 3
Completed
Conditions
Ulcerative Colitis
First Posted Date
2002-05-13
Last Posted Date
2011-05-17
Lead Sponsor
Centocor, Inc.
Target Recruit Count
364
Registration Number
NCT00036439

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
First Posted Date
2002-05-10
Last Posted Date
2011-05-19
Lead Sponsor
Centocor, Inc.
Target Recruit Count
347
Registration Number
NCT00036387

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis, Juvenile
First Posted Date
2002-05-10
Last Posted Date
2011-05-17
Lead Sponsor
Centocor, Inc.
Target Recruit Count
123
Registration Number
NCT00036374

Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis

Phase 2
Completed
Conditions
Dermatomyositis
Polymyositis
First Posted Date
2002-04-12
Last Posted Date
2019-12-03
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
14
Registration Number
NCT00033891
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Infliximab to Treat Children With Juvenile Rheumatoid Arthritis

Phase 2
Terminated
Conditions
Juvenile Rheumatoid Arthritis
First Posted Date
2002-01-07
Last Posted Date
2008-08-27
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
48
Registration Number
NCT00029042
Locations
🇺🇸

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland, United States

Infliximab for the Treatment of Early Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2000-09-25
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
60
Registration Number
NCT00006292
Locations
🇺🇸

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy